Toggle navigation
Home
Search
Services
Blog
Contact
About
Phase 2 Trial: Talabostat in Chronic Lymphocytic Leukemia
Uprichard, Margaret J.
Point Therapeutics, Inc., Boston, MA, United States
Search grants from Margaret Uprichard
Search grants from Point Therapeutics, Inc.
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Ohio State University
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Sleep in fear-entrained mice
Dissecting the function of PI3K/mTOR pathway activation in ROS1 fusion-mediated oncogenesis and resistance to targeted therapy
CRCNS:Dissecting brain-computer interfaces:a manifold &feedback-control approach
Ethanol & Fat Induced Insulin Resistance in the Elderly
1995 Presidential Awardee
Recently added grants:
UNC Neuroscience Center Research Cores: Bioinformatics
Virologic and pharmacologic determinants of dolutegravir failure in East Africa
The Development of Norovirus Immunity in Early Childhood and Implications for Norovirus Vaccines
Mechanistic Studies of AAP and Capsid Assembly of AAV Vectors
Studies on the Biological Mechanisms of Antibiotics
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
Food and Drug Administration (FDA)
Type
Research Project (R01)
Project #
5R01FD003021-02
Application #
7128133
Study Section
Special Emphasis Panel (ZFD1-OPD (01))
Program Officer
Ganti, Usha
Project Start
2005-09-30
Project End
2007-06-30
Budget Start
2006-09-30
Budget End
2007-06-30
Support Year
2
Fiscal Year
2006
Total Cost
Indirect Cost
Institution
Name
Point Therapeutics, Inc.
Department
Type
DUNS #
829400415
City
Boston
State
MA
Country
United States
Zip Code
02110
Related projects
NIH 2006
R01 FD
Phase 2 Trial: Talabostat in Chronic Lymphocytic Leukemia
Uprichard, Margaret J. / Point Therapeutics, Inc.
NIH 2005
R01 FD
Phase 2 Trial: Talabostat in Chronic Lymphocytic Leukemia
Uprichard, Margaret J. / Point Therapeutics, Inc.
Comments
Be the first to comment on Margaret Uprichard's grant